Mineralys Therapeutics Inc. (MLYS): Price and Financial Metrics
MLYS Price/Volume Stats
| Current price | $11.23 | 52-week high | $16.91 |
| Prev. close | $11.94 | 52-week low | $5.85 |
| Day low | $11.10 | Volume | 101,800 |
| Day high | $11.93 | Avg. volume | 183,010 |
| 50-day MA | $12.18 | Dividend yield | N/A |
| 200-day MA | $11.68 | Market Cap | 557.56M |
MLYS Stock Price Chart Interactive Chart >
Latest MLYS News From Around the Web
Below are the latest news stories about MINERALYS THERAPEUTICS INC that investors may wish to consider to help them evaluate MLYS as an investment opportunity.
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the first subject has been dosed in the Launch-HT |
Positive Signs As Multiple Insiders Buy Mineralys Therapeutics StockWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call TranscriptMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Mineralys Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions]. It is now my pleasure to introduce your host, Dan Ferry, of LifeSci Advisors. Please go ahead. Dan Ferry: Thank you, operator. Good afternoon, […] |
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone – – Excess aldosterone in patients with visceral obesity defines a unique hypertensive endotype with potential for an enhanced response to aldosterone-targeted therapy with lorundrostat – – Early identification and intervention with lorundrostat may result in improved clinical outcomes for obese patients with uncontrolled |
Mineralys Therapeutics to Participate in Three Upcoming ConferencesRADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London |
MLYS Price Returns
| 1-mo | 1.91% |
| 3-mo | -16.81% |
| 6-mo | -12.67% |
| 1-year | -5.23% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 30.58% |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...